Last reviewed · How we verify
Period 2 IBI112 dose 3
At a glance
| Generic name | Period 2 IBI112 dose 3 |
|---|---|
| Also known as | IBI112 dose 3, IBI112 dose 4, Placebo |
| Sponsor | Innovent Biologics (Suzhou) Co. Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study to Evaluate IBI112 in the Treatment of Moderate to Severe Active Ulcerative Colitis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Period 2 IBI112 dose 3 CI brief — competitive landscape report
- Period 2 IBI112 dose 3 updates RSS · CI watch RSS
- Innovent Biologics (Suzhou) Co. Ltd. portfolio CI